Free tool
FAERS Monitor: Asmanex Twisthaler
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021067 or its brand name (Asmanex Twisthaler, Mometasone Furoate). Reports on generic versions are filed under their own applications.
Reports
18,509
Serious
9,021
49% of reports
Hospitalization
3,940
Death reported
620
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- no adverse event3,494
- product quality issue2,952
- poor quality device used2,546
- device malfunction1,824
- dyspnoea1,727
- drug dose omission1,496
- asthma1,297
- drug ineffective1,275
- cough1,233
- headache1,147
- product dose omission issue939
- fatigue905
- off label use899
- wheezing763
- nausea745
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 57 |
| 2005 | 57 |
| 2006 | 65 |
| 2007 | 95 |
| 2008 | 152 |
| 2009 | 127 |
| 2010 | 150 |
| 2011 | 153 |
| 2012 | 235 |
| 2013 | 268 |
| 2014 | 629 |
| 2015 | 1,030 |
| 2016 | 1,110 |
| 2017 | 1,079 |
| 2018 | 1,673 |
| 2019 | 1,719 |
| 2020 | 1,386 |
| 2021 | 1,559 |
| 2022 | 1,792 |
| 2023 | 1,327 |
| 2024 | 1,137 |
| 2025 | 1,129 |
| 2026 | 1,580 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,035,650 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| poor quality device usedSignal | 2,546 | 386.0 | 369.9 | 729,809 |
| device malfunctionSignal | 1,824 | 30.3 | 28.9 | 50,398 |
| product quality issueSignal | 2,952 | 25.2 | 24.4 | 67,598 |
| no adverse eventSignal | 3,494 | 22.3 | 21.7 | 70,385 |
| wheezingSignal | 763 | 14.8 | 13.8 | 9,704 |
| asthmaSignal | 1,297 | 13.2 | 12.5 | 14,499 |
| drug dose omissionSignal | 1,496 | 10.4 | 9.9 | 12,639 |
| coughSignal | 1,233 | 5.0 | 4.8 | 3,994 |
| product dose omission issueSignal | 939 | 3.6 | 3.4 | 1,812 |
| dyspnoeaSignal | 1,727 | 3.5 | 3.3 | 3,115 |
| headacheSignal | 1,147 | 2.1 | 2.0 | 661 |
| fatigue | 905 | 1.3 | 1.2 | 73 |
| off label use | 899 | 1.2 | 1.1 | 22 |
| drug ineffective | 1,275 | 1.1 | 1.0 | 12 |
| nausea | 745 | 1.1 | 1.0 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.